Burzynski S R, Burzynski B, Mohabbat M O
Drugs Exp Clin Res. 1986;12 Suppl 1:25-35.
Antineoplaston AS2-1 is a mixture of two products of hydrolysis of Antineoplaston A10 and consists of sodium salts of phenylacetylglutamine and phenylacetic acid in the ratio of 1:4. Antineoplaston AS2-1 injections were administered to 20 patients diagnosed with 21 types of neoplastic diseases. The patients' diagnoses included: lung cancer, stage III, 4 cases; colorectal, stage IV, 3; breast, stage IV, 2; breast in remission, 1; glioblastoma, 3; head and neck, stage IV, 3; uterine cervix, stage IA, 1; chronic myelocytic leukaemia, 2; lymphocytic lymphoma, stage IV, 1; and leiomyosarcoma of the uterus, stage IVB, 1. Antineoplaston AS2-1 was administered every 6 h i.v. through subclavian vein catheter. The treatment was administered from 38 to 872 days. The highest dosage taken was 160 mg/kg/24 h. The treatment was associated with minimal side-effects, including slight nausea and vomiting in one patient, mild allergic reaction in the form of maculopapular rash in another patient and moderate elevation of blood pressure in an additional patient. One patient developed febrile reaction and three patients had mild electrolyte imbalance. Only one patient showed slight decrease of WBC. Desirable side-effects included improved healing of chronic atrophic ulceration. The response to the treatment included 6 complete remissions, 2 partial remissions, 7 cases of stabilization and 6 cases of increasing disease. Three patients are alive, well and free from cancer 5 years after the beginning of the study. The hypothetical mechanism of action of Antineoplaston AS2-1 as an anticancer agent is described.
抗瘤酮AS2-1是抗瘤酮A10两种水解产物的混合物，由苯乙酰谷氨酰胺和苯乙酸的钠盐按1:4的比例组成。对20名被诊断患有21种肿瘤疾病的患者进行了抗瘤酮AS2-1注射治疗。患者的诊断包括：III期肺癌4例；IV期结直肠癌3例；IV期乳腺癌2例；缓解期乳腺癌1例；胶质母细胞瘤3例；IV期头颈部癌3例；IA期子宫颈癌1例；慢性粒细胞白血病2例；IV期淋巴细胞淋巴瘤1例；IVB期子宫平滑肌肉瘤1例。抗瘤酮AS2-1通过锁骨下静脉导管每6小时静脉注射一次。治疗持续38至872天。最高剂量为160mg/kg/24小时。该治疗的副作用极小，包括1例患者出现轻微恶心和呕吐，另1例患者出现斑丘疹形式的轻度过敏反应，还有1例患者血压中度升高。1例患者出现发热反应，3例患者有轻度电解质失衡。只有1例患者白细胞略有下降。理想的副作用包括慢性萎缩性溃疡愈合改善。治疗反应包括6例完全缓解、2例部分缓解、7例病情稳定和6例病情进展。3例患者在研究开始5年后存活，身体健康且无癌症。文中描述了抗瘤酮AS2-1作为抗癌药物的假设作用机制。
